These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 25619868)

  • 41. Immunophenotypic Heterogeneity of Polytypic Plasma Cells and the Impact on Myeloma Minimal Residual Disease Detection by Multiparameter Flow Cytometry.
    Schouweiler KE; Karandikar NJ; Holman CJ
    Cytometry B Clin Cytom; 2019 Jul; 96(4):310-318. PubMed ID: 31140731
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry.
    Takamatsu H; Yoroidaka T; Fujisawa M; Kobori K; Hanawa M; Yamashita T; Murata R; Ueda M; Nakao S; Matsue K
    Int J Hematol; 2019 Apr; 109(4):377-381. PubMed ID: 30778767
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection.
    Ciudad J; Orfao A; Vidriales B; Macedo A; Martínez A; González M; López-Berges MC; Valverde B; San Miguel JF
    Haematologica; 1998 Dec; 83(12):1069-75. PubMed ID: 9949623
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
    Schmitz A; Brøndum RF; Johnsen HE; Mellqvist UH; Waage A; Gimsing P; Op Bruinink DH; van der Velden V; van der Holt B; Hansson M; Andersen NF; Frølund UC; Helleberg C; Schjesvold FH; Ahlberg L; Gulbrandsen N; Andreasson B; Lauri B; Haukas E; Bødker JS; Roug AS; Bøgsted M; Severinsen MT; Gregersen H; Abildgaard N; Sonneveld P; Dybkær K
    BMC Cancer; 2022 Feb; 22(1):147. PubMed ID: 35123422
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry.
    Alaterre E; Raimbault S; Garcia JM; Rème T; Requirand G; Klein B; Moreaux J
    Cytometry B Clin Cytom; 2018 May; 94(3):484-492. PubMed ID: 28865180
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Utility and feasibility of a six-color multiparametric flow cytometry for measurable residual disease analysis in plasma cell myeloma in resource-limited settings with 5-year survival data.
    Sharma P; Singh Sachdeva MU; Varma N; Bose P; Aggarwal R; Malhotra P
    J Cancer Res Ther; 2021; 17(6):1515-1520. PubMed ID: 34916387
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry.
    Soh KT; Tario JD; Wallace PK
    Clin Lab Med; 2017 Dec; 37(4):821-853. PubMed ID: 29128071
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma.
    Bae MH; Park CJ; Kim BH; Cho YU; Jang S; Lee DH; Seo EJ; Yoon DH; Lee JH; Suh C
    Cytometry B Clin Cytom; 2018 May; 94(3):493-499. PubMed ID: 29220877
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Six color flow cytometry detects plasma cells expressing aberrant immunophenotype in bone marrow of healthy donors.
    Peceliunas V; Janiulioniene A; Matuzeviciene R; Griskevicius L
    Cytometry B Clin Cytom; 2011 Sep; 80(5):318-23. PubMed ID: 21634008
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Standardizing minimal residual disease by flow cytometry for precursor B lineage acute lymphoblastic leukemia in a developing country.
    Patkar N; Alex AA; B B; Ahmed R; Abraham A; George B; Vishwabandya A; Srivastava A; Mathews V
    Cytometry B Clin Cytom; 2012 Jul; 82(4):252-8. PubMed ID: 22467604
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Participation in the College of American Pathologists Laboratory Accreditation Program Decreases Variability in B-Lymphoblastic Leukemia and Plasma Cell Myeloma Flow Cytometric Minimal Residual Disease Testing: A Follow-up Survey.
    Hupp MM; Bashleben C; Cardinali JL; Dorfman DM; Karlon W; Keeney M; Leith C; Long T; Murphy CE; Pillai V; Rosado FN; Seegmiller AC; Linden MA
    Arch Pathol Lab Med; 2021 Mar; 145(3):336-342. PubMed ID: 32886757
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Flow cytometric DNA quantification in immunophenotyped cells as a sensitive method for determination of aneuploid multiple myeloma cells in peripheral blood stem cell harvests and bone marrow after therapy.
    Nowak R; Oelschlägel U; Range U; Bergmann S; Bornhäuser M; Hölig C; Schuler U; Krebs U; Günther H; Kroschinsky F; Ehninger G
    Bone Marrow Transplant; 1999 May; 23(9):895-900. PubMed ID: 10338044
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Utility of 8-colours multiparameter flow cytometry immunophenotyping of plasma cells for the management of monoclonal gammopathy].
    Gressier M; Chaquin M; Lhermitte L; Asnafi V; Macintyre E; Brouzes C
    Ann Biol Clin (Paris); 2013; 71(3):313-23. PubMed ID: 23747669
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The immunophenotypic stability of plasma cell myeloma by flow cytometry.
    Spears MD; Olteanu H; Kroft SH; Harrington AM
    Int J Lab Hematol; 2011 Oct; 33(5):483-91. PubMed ID: 21470371
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: An international harmonized approach for data analysis.
    Soh KT; Came N; Otteson GE; Jevremovic D; Shi M; Olteanu H; Natoni A; Lagoo A; Theakston E; Óskarsson JÞ; Gorniak M; Grigoriadis G; Arroz M; Fletcher M; Lin P; Ludwig P; Tembhare P; Matuzeviciene R; Radzevicius M; Kay S; Chen W; Cabrita C; Wallace PK
    Cytometry B Clin Cytom; 2022 Mar; 102(2):88-106. PubMed ID: 35005838
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Research progress on multiple myeloma immunophenotyping and minimal residual disease detected by flow cytometry].
    Li HQ; Zhai YP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Feb; 23(1):241-5. PubMed ID: 25687080
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.
    Ocqueteau M; Orfao A; Almeida J; Bladé J; González M; García-Sanz R; López-Berges C; Moro MJ; Hernández J; Escribano L; Caballero D; Rozman M; San Miguel JF
    Am J Pathol; 1998 Jun; 152(6):1655-65. PubMed ID: 9626070
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of an unbiased, semi-automated approach for classifying plasma cell immunophenotype following multicolor flow cytometry of bone marrow aspirates.
    Post SR; Post GR; Nikolic D; Owens R; Insuasti-Beltran G
    Cytometry B Clin Cytom; 2018 Sep; 94(5):602-610. PubMed ID: 29573142
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunophenotyping of plasma cells.
    Rawstron AC
    Curr Protoc Cytom; 2006 May; Chapter 6():Unit6.23. PubMed ID: 18770841
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study.
    Liu H; Yuan C; Heinerich J; Braylan R; Chang M; Wingard J; Moreb J
    Leuk Lymphoma; 2008 Feb; 49(2):306-14. PubMed ID: 18231918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.